NCT07393373 Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia Status ENROLLING_BY_INVITATION Phase PHASE2
NCT06206278 Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma Status TERMINATED Phase PHASE2
NCT05510427 Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification Status WITHDRAWN Phase PHASE1
NCT05222165 Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations Status WITHDRAWN Phase PHASE1/PHASE2
NCT05145010 Extension Study of Infigratinib in Children With Achondroplasia (ACH) Status ENROLLING_BY_INVITATION Phase PHASE2
NCT05019794 Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations Status UNKNOWN Phase PHASE2
NCT04504331 Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer Status TERMINATED Phase PHASE1
NCT04424966 Infigratinib in Recurrent High-Grade Glioma Patients Status TERMINATED Phase EARLY_PHASE1
NCT04233567 Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Status COMPLETED Phase PHASE2
NCT04228042 Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT04197986 Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations Status TERMINATED Phase PHASE3